Skip to main content

Advertisement

SpringerLink
Log in

The Efficacy and Safety of Newer Anticonvulsants in Patients with Dementia

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Anticonvulsants are a class of medications that have received considerable interest as possible treatments in patients with behavioural disturbances in dementia. The role of these medications for such a use remains controversial. The current paper reviews the published evidence surrounding the safety and efficacy (i.e. as a behavioural and cognitive treatment) of newer anticonvulsants in patients with dementia. A MEDLINE, International Pharmaceutical Abstracts, PsycINFO and clinicaltrials.gov search through to December 2011 was conducted for anticonvulsants that have received regulatory approval since 1996. Studies reporting behavioural or cognitive outcomes in patients with dementia were included. Nine trials involving only four medications met selection criteria and were included: levetiracetam (n = 4), oxcarbazepine (n = 1), topiramate (n = 2) and zonisamide (n = 2). Levetiracetam may have a role in the treatment of behavioural symptoms in dementia but study limitations substantially hinder the strength of such a recommendation. Oxcarbazepine and topiramate, based on limited data, do not appear to be effective treatments of behavioural symptoms in dementia. A lack of trials do not allow for conclusions to be made regarding zonisamide. From a cognitive standpoint, levetiracetam was the anticonvulsant most examined in patients with dementia, it appears to have less deleterious effects than some anticonvulsants. Limited data are available on the safety of these medications in elderly patients; however, studies completed thus far have demonstrated some adverse events that are more common or problematic with the use of these drugs in this patient population (i.e. somnolence, dizziness, hyponatraemia, weight loss).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. American Psychiatric Association: Treatment of patients with Alzheimer’s disease and other dementias. 2nd ed. 2007 Oct [online]. Available from URL: http://psychiatryonline.org/data/Books/prac/AlzPG101007.pdf [Accessed 2011 Oct 4].

  2. American Academy of Neurology. Practice parameter: management of dementia. 2003 Oct [online]. Available from URL: http://www.neurology.org/content/56/9/1154.full.pdf [Accessed 2011 Oct 4].

  3. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006 Jul; 14 (7): 561–72.

    Article  PubMed  Google Scholar 

  4. Jalbert JJ, Eaton CB, Miller SC. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010; 11: 120–7.

    Article  PubMed  Google Scholar 

  5. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999 Jan; 47 (1): 40–50.

    PubMed  CAS  Google Scholar 

  6. Mehta S, Chen H, Johnson ML, et al. Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging 2010 Oct 1; 27 (10): 815–29.

    Article  PubMed  Google Scholar 

  7. Mehta S, Johnson ML, Chen H, et al. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry 2010 Jun; 71 (6): 689–98.

    Article  PubMed  Google Scholar 

  8. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010 Sep 21; 341: c4245.

    Article  PubMed  Google Scholar 

  9. Rossom RC, Rector TS, Lederle FA, et al. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 2010 Jun; 58 (6): 1027–34.

    Article  PubMed  Google Scholar 

  10. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006 Mar; 14 (3): 191–210.

    Article  PubMed  Google Scholar 

  11. United States Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. 2008 Jun 16 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm [Accessed 2011 Feb 4].

  12. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009 Jan 15; 360 (3): 225–35.

    Article  PubMed  CAS  Google Scholar 

  13. Bierman EJ, Comijs HC, Gundy CM, et al. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry 2007 Dec; 22 (12): 1194–200.

    Article  PubMed  CAS  Google Scholar 

  14. Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006 Feb; 54 (2): 224–30.

    Article  PubMed  Google Scholar 

  15. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999 Aug; 21 (2): 101–22.

    Article  PubMed  CAS  Google Scholar 

  16. Lavsa SM, Fabian TJ, Saul MI, et al. Influence of medications and diagnoses on fall risk in psychiatric inpatients. Am J Health Syst Pharm 2010 Aug; 67 (15): 1274–80.

    Article  PubMed  Google Scholar 

  17. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Int Med 2004 Jul 26; 164 (14): 1567–72.

    Article  Google Scholar 

  18. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Int Med 2009 Nov 23; 169 (21): 1952–60.

    Article  Google Scholar 

  19. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002 Mar; 159 (3): 460–5.

    Article  PubMed  Google Scholar 

  20. Pollock BG, Mulsant BH, Sweet R, et al. An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations. Am J Geriatr Psychiatry 1997 Winter; 5 (1): 70–8.

    PubMed  CAS  Google Scholar 

  21. Dolder CR, Nealy KL, McKinsey J. Valproic acid in dementia: Does an optimal dose exist? J Pharm Pract. Epub 2011 Nov 17.

  22. Grossman F. A review of anticonvulsants in treating agitated demented elderly patients. Pharmacotherapy 1998 May–Jun; 18 (3): 600–6.

    PubMed  CAS  Google Scholar 

  23. Herrmann N, Lanctot KL. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007 Oct; 52 (10): 630–46.

    PubMed  Google Scholar 

  24. Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006; 23 (11): 877–86.

    Article  PubMed  CAS  Google Scholar 

  25. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005 Feb 2; 293 (5): 596–608.

    Article  PubMed  CAS  Google Scholar 

  26. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry Aug; 68 (8): 853–61.

  27. Amann B, Pantel J, Grunze H, et al. Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clin Pract Epidemiol Ment Health 2009; 5: 14.

    Article  PubMed  Google Scholar 

  28. Guay DR. Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability. Consult Pharm 2007 Dec; 22 (12): 1004–34.

    Article  PubMed  Google Scholar 

  29. Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opin Drug Saf 2007 Mar; 6 (2): 133–45.

    Article  PubMed  CAS  Google Scholar 

  30. Sajatovic M, Ramsay E, Nanry K, et al. Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. Int J Geriatr Psychiatry 2007 Oct; 22 (10): 945–50.

    Article  PubMed  Google Scholar 

  31. Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology 1986 Sep; 36 (9): 1226–30.

    Article  PubMed  CAS  Google Scholar 

  32. Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology 1996 Mar; 46 (3): 727–30.

    Article  PubMed  CAS  Google Scholar 

  33. Larner AJ. Epileptic seizures in AD patients. Neuromolecular Med 2010 Mar; 12 (1): 71–7.

    Article  PubMed  CAS  Google Scholar 

  34. Romanelli MF, Morris JC, Ashkin K, et al. Advanced Alzheimer’s disease is a risk factor for late-onset seizures. Arch Neurol 1990 Aug; 47 (8): 847–50.

    Article  PubMed  CAS  Google Scholar 

  35. Forsgren L, Bucht G, Eriksson S, et al. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996 Mar; 37 (3): 224–9.

    Article  PubMed  CAS  Google Scholar 

  36. Hommet C, Hureaux R, Barre J, et al. Epileptic seizures in clinically diagnosed Alzheimer’s disease: report from a geriatric medicine population. Aging Clin Exp Res 2007 Oct; 19 (5): 430–1.

    PubMed  Google Scholar 

  37. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003; 20 (11): 791–803.

    Article  PubMed  CAS  Google Scholar 

  38. Rao SC, Dove G, Cascino GD, et al. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav 2009 Jan; 14 (1): 118–20.

    Article  PubMed  Google Scholar 

  39. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011 May; 7 (3): 263–9.

    Article  PubMed  Google Scholar 

  40. Ebell MH, Siwek J, Weiss BD, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004 Feb 1; 69 (3): 548–56.

    PubMed  Google Scholar 

  41. Sommer OH, Aga O, Cvancarova M, et al. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord 2009; 27 (2): 155–63.

    Article  PubMed  CAS  Google Scholar 

  42. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav 2010 Apr; 17 (4): 461–6.

    Article  PubMed  Google Scholar 

  43. Lippa CF, Rosso A, Hepler M, et al. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Demen 2010 Mar; 25 (2): 149–54.

    Article  PubMed  Google Scholar 

  44. Kyomen HH, Whitfield TH, Baldessarini RJ. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer’s type. J Clin Psychopharmacol 2007 Aug; 27 (4): 408–10.

    Article  PubMed  Google Scholar 

  45. Weiner MF, Womack KB, Martin-Cook K, et al. Levetiracetam for agitated Alzheimer’s disease patients. Int Psychogeriatr 2005 Jun; 17 (2): 327–8.

    Article  PubMed  Google Scholar 

  46. Mowla A, Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 2010 Feb; 30 (1): 40–3.

    Article  PubMed  CAS  Google Scholar 

  47. Fhager B, Meiri IM, Sjogren M, et al. Treatment of aggressive behavior in dementia with the anticonvulsant to-piramate: a retrospective pilot study. Int Psychogeriatr 2003 Sep; 15 (3): 307–9.

    Article  PubMed  Google Scholar 

  48. Odawara T, Shiozaki K, Togo T, et al. Administration of zonisamide in three cases of dementia with Lewy bodies. Psychiatry Clin Neurosci 2010 Jun; 64 (3): 327–9.

    Article  PubMed  Google Scholar 

  49. Sato S, Mizukami K, Asada T. Successful treatment of extrapyramidal and psychotic symptoms with zonisamide in a patient with dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry 2010 Aug 16; 34 (6): 1130–1.

    Article  PubMed  Google Scholar 

  50. Belcastro V, Costa C, Galletti F, et al. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 2007 Oct; 14 (10): 1176–8.

    Article  PubMed  CAS  Google Scholar 

  51. Zesiewicz TA, Sullivan KL, Hauser RA, et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease. Mov Disord 2006 Nov; 21 (11): 1998–2001.

    Article  PubMed  Google Scholar 

  52. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 4].

  53. Kutluay E, McCague K, D’Souza J, et al. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003 Apr; 4 (2): 175–80.

    Article  PubMed  Google Scholar 

  54. Chapman IM. Weight loss in older persons. Med Clin North Am 2011 May; 95 (3): 579–93, xi.

    Article  PubMed  Google Scholar 

  55. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007 Jan 2; 68 (1): 45–50.

    Article  PubMed  CAS  Google Scholar 

  56. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 Suppl. 4: 21–9.

    Article  PubMed  CAS  Google Scholar 

  57. Sempere AP, Medrano V, Berenguer-Ruiz L. Reversible dementia secondary to topiramate. Clin Neuropharmacol 2008 Jan-Feb; 31 (1): 62.

    Article  PubMed  Google Scholar 

  58. Lexicomp Online [subscription, online database]. Hudson (OH): Lexi-Comp, Inc., 2012 [online]. Available from URL: http://www.lexi.com [Accessed 2011 Feb 4].

  59. Cicolin A, Magliola U, Giordano A, et al. Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers. Epilepsia 2006 Jan; 47 (1): 82–5.

    Article  PubMed  CAS  Google Scholar 

  60. Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res 2006 Jan; 68 (1): 63–7.

    Article  PubMed  Google Scholar 

  61. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45 (4): 351–63.

    Article  PubMed  CAS  Google Scholar 

  62. Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995 May; 19 (3): 411–9.

    Article  PubMed  CAS  Google Scholar 

  63. Alsaadi TM, Koopmans S, Apperson M, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 2004 Jan; 13 (1): 58–60.

    Article  PubMed  Google Scholar 

  64. Cramer JA, Leppik IE, Rue KD, et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003 Oct; 56 (2–3): 135–45.

    Article  PubMed  CAS  Google Scholar 

  65. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999 Sep; 1 (1): 42–53.

    Article  PubMed  CAS  Google Scholar 

  66. White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41 Suppl. 1: S17–20.

    Article  PubMed  CAS  Google Scholar 

  67. Mitchell PB, Malhi GS. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002; 53: 173–88.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no actual or potential conflicts of interest to disclose. All work related to the manuscript was completed as part of the authors’ regular job duties; no additional funding was used in preparation of the manuscript.

Author information

Authors and Affiliations

  1. Wingate University School of Pharmacy, 515 N. Main St., Wingate, North Carolina, NC 28174, USA

    Christian R. Dolder PharmD, BCPS & Kimberly L. Nealy

  2. Pharmacy Department, Carolinas Medical Center-NorthEast, Concord, North Carolina, USA

    Christian R. Dolder PharmD, BCPS

  3. Pharmacy Department, Carolinas Medical Center-Main, Charlotte, North Carolina, USA

    Kimberly L. Nealy

Authors
  1. Christian R. Dolder PharmD, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberly L. Nealy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian R. Dolder PharmD, BCPS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dolder, C.R., Nealy, K.L. The Efficacy and Safety of Newer Anticonvulsants in Patients with Dementia. Drugs Aging 29, 627–637 (2012). https://doi.org/10.1007/BF03262279

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262279

Keywords

Search

Navigation